Natixis’s West Pharmaceutical WST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.41M | Sell |
17,576
-11,082
| -39% | -$2.76M | 0.02% | 457 |
|
|
2025
Q4 | $7.88M | Buy |
28,658
+14,241
| +99% | +$3.9M | 0.03% | 377 |
|
|
2025
Q3 | $3.78M | Buy |
14,417
+2,231
| +18% | +$542K | 0.02% | 483 |
|
|
2025
Q2 | $2.67M | Buy |
12,186
+5,717
| +88% | +$1.22M | 0.01% | 440 |
|
|
2025
Q1 | $1.44M | Buy |
6,469
+2,060
| +47% | +$568K | 0.01% | 496 |
|
|
2024
Q4 | $1.44M | Buy |
+4,409
| New | +$1.39M | 0.01% | 540 |
|
|
2024
Q3 | – | Sell |
-1,178
| Closed | -$388K | – | 1139 |
|
|
2024
Q2 | $388K | Sell |
1,178
-19,132
| -94% | -$6.76M | ﹤0.01% | 642 |
|
|
2024
Q1 | $8.04M | Buy |
20,310
+17,368
| +590% | +$6.42M | 0.04% | 267 |
|
|
2023
Q4 | $1.04M | Buy |
2,942
+1,881
| +177% | +$666K | 0.01% | 520 |
|
|
2023
Q3 | $398K | Sell |
1,061
-3,585
| -77% | -$1.39M | ﹤0.01% | 643 |
|
|
2023
Q2 | $1.78M | Buy |
+4,646
| New | +$1.66M | 0.01% | 448 |
|
|
2023
Q1 | – | Sell |
-9,646
| Closed | -$2.27M | – | 1225 |
|
|
2022
Q4 | $2.27M | Buy |
9,646
+4,728
| +96% | +$1.12M | 0.01% | 515 |
|
|
2022
Q3 | $1.21M | Buy |
4,918
+1,152
| +31% | +$351K | 0.01% | 720 |
|
|
2022
Q2 | $1.14M | Buy |
3,766
+302
| +9% | +$98.3K | ﹤0.01% | 794 |
|
|
2022
Q1 | $1.42M | Sell |
3,464
-12,514
| -78% | -$4.9M | 0.01% | 815 |
|
|
2021
Q4 | $7.49M | Buy |
15,978
+12,771
| +398% | +$5.5M | 0.03% | 464 |
|
|
2021
Q3 | $1.36M | Buy |
+3,207
| New | +$1.35M | ﹤0.01% | 808 |
|
|
2021
Q2 | – | Sell |
-25,332
| Closed | -$7.14M | – | 1121 |
|
|
2021
Q1 | $7.14M | Sell |
25,332
-13,287
| -34% | -$3.8M | 0.02% | 439 |
|
|
2020
Q4 | $10.9M | Sell |
38,619
-20,227
| -34% | -$5.68M | 0.04% | 374 |
|
|
2020
Q3 | $16.2M | Sell |
58,846
-3,402
| -5% | -$900K | 0.12% | 158 |
|
|
2020
Q2 | $14.1M | Buy |
62,248
+49,027
| +371% | +$9.63M | 0.11% | 154 |
|
|
2020
Q1 | $2.01M | Buy |
+13,221
| New | +$2.03M | 0.02% | 384 |
|
|
2019
Q4 | – | Sell |
-25,249
| Closed | -$3.58M | – | 981 |
|
|
2019
Q3 | $3.58M | Sell |
25,249
-35,703
| -59% | -$4.92M | 0.02% | 404 |
|
|
2019
Q2 | $7.63M | Buy |
60,952
+34,341
| +129% | +$4.05M | 0.06% | 258 |
|
|
2019
Q1 | $2.86M | Buy |
+26,611
| New | +$2.77M | 0.02% | 455 |
|
|
2018
Q3 | – | Sell |
-2,551
| Closed | -$253K | – | 993 |
|
|
2018
Q2 | $253K | Buy |
+2,551
| New | +$235K | ﹤0.01% | 788 |
|
|
2018
Q1 | – | Sell |
-2,607
| Closed | -$257K | – | 985 |
|
|
2017
Q4 | $257K | Sell |
2,607
-3,079
| -54% | -$302K | ﹤0.01% | 721 |
|
|
2017
Q3 | $547K | Buy |
5,686
+33
| +0.6% | +$2.99K | 0.01% | 656 |
|
|
2017
Q2 | $534K | Buy |
5,653
+1,272
| +29% | +$117K | 0.01% | 507 |
|
|
2017
Q1 | $358K | Buy |
4,381
+1,803
| +70% | +$151K | ﹤0.01% | 624 |
|
|
2016
Q4 | $219K | Buy |
+2,578
| New | +$203K | ﹤0.01% | 775 |
|
Other funds holding WST
VCM
VPM
GIM
Natixis's WST Position: Q1 2026 in Review
Natixis reduced its West Pharmaceutical (WST) stake by 39% in Q1 2026, selling an estimated $2.76M and leaving 17,576 shares worth $4.41M. The position accounts for 0.02% of the portfolio, ranked #457.
Natixis first reported a position in WST in Q4 2016 and has held it in 31 quarters since. The position peaked at $16.2M in Q3 2020. 754 funds tracked by Wall St. Rank hold WST as of Q1 2026.
- Natixis held 17,576 shares of West Pharmaceutical worth $4.41M as of Q1 2026.
- Natixis sold 11,082 West Pharmaceutical shares in Q1 2026, an estimated $2.76M.
- West Pharmaceutical made up 0.02% of Natixis's portfolio in Q1 2026, its #457 holding.
- Natixis first reported a position in West Pharmaceutical in Q4 2016 and has held it in 31 quarters since.
- Natixis's West Pharmaceutical position peaked at $16.2M in Q3 2020.
- 754 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.
Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.